Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025
Crofelemer正在進行五個臨床研究，其中包括三項概念驗證的研究者主導試驗(IIT)和兩項第二階段研究，針對美國、歐洲及中東/北非地區的微絨毛包容性疾病(MVID)和/或腸功能不全的短腸綜合症(SBS-IF)這一罕見疾病；IIT概念驗證結果預計在2025年第二季度可用。
Virtual event 11:00 AM to 12:00 PM Eastern
虛擬活動時間爲東部時間上午11:00至中午12:00。
Registration open now for financial and business community; Click here to register
現已對金融和業務社區開放註冊；點擊這裏註冊。
Massimo Radaelli, PhD, CEO of the rare disease-focused Jaguar family company Napo Therapeutics and President of Jaguar International, named 'Best CEO BioPharmaceuticals of the Year'
專注於罕見疾病的Jaguar家族公司Napo Therapeutics 的首席執行官Massimo Radaelli博士，同時也是Jaguar International的總裁，被評爲「年度生物製藥最佳首席執行官」。
SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Ladenburg Thalmann is hosting a Scientific Showcase webinar on Wednesday, December 18, 2024 from 11:00 a.m. to 12:00 p.m. EST about clinical development efforts for crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the ultrarare congenital diarrheal disorder MVID and the rare disease SBS-IF. To register for this virtual event, which is open to the financial and business community, click here.
加利福尼亞州舊金山 / ACCESSWIRE / 2024年12月13日 / Jaguar Health, Inc. (NASDAQ:JAGX)（Jaguar）今天宣佈，Ladenburg Thalmann將在2024年12月18日（星期三）上午11:00至中午12:00（東部時間）舉辦關於crofelemer的臨床開發努力的科學展示網絡研討會，這是Jaguar創新的植物基止瀉處方藥，旨在治療超罕見的先天性腹瀉疾病MVID和罕見疾病SBS-IF。要註冊這個面向金融和業務社區的虛擬活動，請點擊這裏。
Jaguar founder and CEO Lisa Conte and Pravin Chaturvedi, PhD, Jaguar's Chief Scientific Officer and Chair of the company's Scientific Advisory Board, will participate in the virtual event.
Jaguar的創始人兼首席執行官Lisa Conte和Jaguar的首席科學官及公司科學顧問委員會主席Pravin Chaturvedi博士將參加該虛擬活動。
Participation Instructions for Scientific Showcase
科學展示的參與說明
Event is exclusively for investors, financial analysts, business media, and business development executives.
本次活動僅面向投資者、金融分析師、商業媒體和業務發展高管。
When: Wednesday, December 18, 2024 from 11:00 a.m. to 12:00 p.m. EST
時間：2024年12月18日星期三，美國東部時間上午11:00至中午12:00
Registration Link: Click Here
註冊鏈接：點擊這裏
"We're thrilled to announce that Massimo Radaelli, PhD, CEO of the rare disease-focused Jaguar family company Napo Therapeutics and President of Jaguar International, has been named "Best Pharmaceuticals Innovator of the Year - Europe" by The European, a quarterly business publication published by CP Media Global Ltd in London," said Lisa Conte, Jaguar's president and CEO. "This award is well deserved, reflecting Massimo's lifetime of dedication and pioneering vision in the industry. As announced last month, The European also named Napo Therapeutics "Best Pharmaceuticals Innovator of the Year - Europe" for 2024 - additional welcome recognition of ongoing efforts by Massimo and Napo Therapeutics to expand access to crofelemer in Europe for orphan and/or rare diseases, initially for MVID and SBS-IF."
「我們很高興地宣佈，專注於罕見疾病的Jaguar家族公司Napo Therapeutics的首席執行官Massimo Radaelli博士，以及Jaguar International的總裁，被《歐洲》雜誌評選爲『歐洲年度最佳藥品創新者』，」Jaguar的總裁兼首席執行官Lisa Conte表示。「這一獎項實至名歸，反映了Massimo在行業中的一生奉獻和開創性視野。正如上個月宣佈的，《歐洲》雜誌還將Napo Therapeutics評選爲2024年『歐洲年度最佳藥品創新者』——這是對Massimo和Napo Therapeutics持續努力擴大crofelemer在歐洲對孤兒和/或罕見疾病的可及性的另一個良好認可，最初針對MVID和SBS-IF。」
About the Jaguar Health Family of Companies
關於Jaguar Health公司家族
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
Jaguar Health, Inc.（Jaguar）是一家商業階段的製藥公司，專注於開發從雨林地區可持續來源植物中提取的獨特處方藥，旨在幫助人類和動物緩解腸道不適，特別是與腸道過度活躍相關的症狀，包括慢性虛弱性腹瀉、緊迫感、腸道失禁和腹部痙攣。Jaguar家族公司Napo Pharmaceuticals（Napo）專注於開發和商業化人類處方藥，用於重要的支持性護理和管理多個複雜疾病狀態中的被忽視的腸道症狀。Napo的crofelemer在FDA已批准，品牌名稱爲Mytesi，用於HIV/AIDS患者在抗逆轉錄病毒治療中非感染性腹瀉的症狀緩解。Jaguar家族公司Napo Therapeutics是一家意大利公司，於2021年在意大利米蘭成立，專注於擴大歐洲特別是孤兒和/或罕見疾病對crofelemer的可及性。Jaguar Animal Health是Jaguar的商標名。Magdalena Biosciences是Jaguar和Filament Health Corp.共同成立的合資企業，該企業源於Jaguar的Entheogen Therapeutics Initiative（ETI），專注於開發用於心理健康指示的植物衍生處方藥。
For more information about:
有關更多信息，請訪問：
Jaguar Health, visit
請訪問jaguar health。
Napo Pharmaceuticals, visit
Napo Pharmaceuticals，訪問
Napo Therapeutics, visit napotherapeutics.com
Napo Therapeutics，訪問 napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Magdalena Biosciences，訪問 magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
訪問Bluesky、X、Facebook和Instagram上的Make Cancer Less Shitty患者倡導項目
Forward-Looking Statements
前瞻性聲明
Certain statements in this press release constitute "forward-looking statements." These include statements related to the expectation that Ladenburg Thalmann will host a Scientific Showcase on December 18, 2024 about Jaguar Health's rare disease clinical development efforts, and Jaguar's expectation that availability of IIT proof-of-concept results of crofelemer in MVID and/or SBS-IF may potentially occur in Q2 2025. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
本新聞稿中的某些陳述構成「前瞻性陳述」。這些陳述包括與Ladenburg Thalmann將在2024年12月18日舉辦關於Jaguar Health稀有疾病臨床開發工作的科學展示相關的期望，以及Jaguar對crofelemer在MVID和/或SBS-IF中的IIt概念驗證結果可能在2025年第二季度出現的期望。在某些情況下，您可以通過像「可能」、「將」、「應該」、「期望」、「計劃」、「目標」、「預期」、「能夠」、「打算」、「目標」、「項目」、「考慮」、「相信」、「估計」、「預測」、「潛在」或「繼續」等術語或這些術語的否定形式或其他類似的表達來識別前瞻性陳述。本發佈中的前瞻性陳述僅爲預測。Jaguar主要基於其當前的期望和關於未來事件的預測來制定這些前瞻性陳述。這些前瞻性陳述僅在本發佈之日期有效，並受幾個風險、不確定性和假設的影響，其中一些是不可預測或不可量化的，並且有些超出了Jaguar的控制範圍。除非法律要求，Jaguar不計劃公開更新或修訂本文件中包含的任何前瞻性陳述，無論是由於任何新信息、未來事件、改變的情況還是其他原因。
Contact:
聯繫：
hello@jaguar.health
hello@jaguar.health
Jaguar-JAGX
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
資料來源：Jaguar Health, Inc。
譯文內容由第三人軟體翻譯。
